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Abstract. Osteosarcoma (OS) is the most common type of 
bone cancer, with a peak incidence in the early childhood. 
Emerging evidence suggests that treatments targeting cancer 
stem cells (CSCs) within a tumor can halt cancer and improve 
patient survival. MicroRNAs (miRNAs) have been implicated 
in the maintenance of the CSC phenotype, thus, identification 
of CSC-related miRNAs would provide information for a 
better understanding of CSCs. Downregulation of miRNA-29 
family members (miR-29a/b/c; miR-29s) was observed in 
human OS, however, little is known about the functions of 
miR-29s in human OS CSCs. Previously, during the charac-
terization of 3AB-OS cells, a CSC line selected from human 
OS MG63 cells, we showed a potent downregulation of 
miR-29b. In this study, after stable transfection of 3AB-OS 
cells with miR-29b-1, we investigated the role of miR-29b-1 
in regulating cell proliferation, sarcosphere-forming ability, 
clonogenic growth, chemosensitivity, migration and invasive 
ability of 3AB-OS cells, in vitro. We found that, miR-29b-1 
overexpression consistently reduced both, 3AB-OS CSCs 
growth in two- and three-dimensional culture systems and 
their sarcosphere- and colony-forming ability. In addition, 
while miR-29b-1 overexpression sensitized 3AB-OS cells to 
chemotherapeutic drug-induced apoptosis, it did not influence 
their migratory and invasive capacities, thus suggesting a 
context-depending role of miR-29b-1. Using publicly avail-
able databases, we proceeded to identify potential miR-29b 
target genes, known to play a role in the above reported 
functions. Among these targets we analyzed CD133, N-Myc, 
CCND2, E2F1 and E2F2, Bcl-2 and IAP-2. We also analyzed 
the most important stemness markers as Oct3/4, Sox2 and 
Nanog. Real-time RT-PCR and western-blot analyses showed 
that miR-29b-1 negatively regulated the expression of these 
markers. Overall, the results show that miR-29b-1 suppresses 
stemness properties of 3AB-OS CSCs and suggest that devel-
oping miR-29b-1 as a novel therapeutic agent might offer 
benefits for OS treatment.
Introduction
Osteosarcoma (OS), a highly aggressive tumor with a potent 
metastasizing potential, is the most common form of child-
hood cancer, comprising 2.4% of all malignancies in pediatric 
patients, and ~20% of all primary bone cancers (1,2). The 
current standard chemotherapy regimen (cisplatin, doxo-
rubicin and methotrexate) provides only 65-70% long-term 
disease-free survival for OS patients without metastasis (3). 
Moreover, there is no established second-line chemotherapy 
for relapsed OS (4).
It is universally acknowledged that a successful cure of 
cancer requires the eradication of cancer stem cells (CSCs) (5), 
a subpopulation of cells which is the source for tissue renewal 
and hold malignant potential (6,7), and which confers resis-
tance to therapies.
Previously (8), treating the human OS MG63 cells with 
3-aminobenzamide (3AB), a potent inhibitor of poly(ADP-
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ribose) polymerase (PARP), we produced, isolated and patented 
for the first time a human OS CSC line which has been termed 
3AB-OS. 3AB-OS cells are a heterogeneous and stable cell 
population which possesses properties (self-renewal and pluri-
potency in vitro, tumorigenicity in vivo) that indicated them 
as CSCs (9,10). Moreover, they also express a large number of 
genes required for maintaining stemness, controlling cell cycle 
(in particular G1-S/G2-M phases progression) and inhibiting 
apoptosis. 3AB-OS CSCs have been characterized at genetic 
and molecular level (11). In comparison with parental MG63 
cells, they are hypertriploid with a higher chromosome number 
ranging from 71 to 82. They also exhibit 49 copy number 
variations spanning almost all the chromosomes and 3,512 
dysregulated genes. Moreover, they exhibit 189 differentially 
expressed (up-/downregulated) microRNAs (miRNAs).
MiRNAs are a novel class of small non-coding RNAs that 
regulate gene expression at the translational or post-transcrip-
tional level by repressing translation from protein-encoding 
messenger RNAs (mRNAs) or by promoting degradation 
of their target mRNAs (12). Many studies have shown that 
miRNAs are aberrantly regulated in human cancers, suggesting 
a role as a novel class of oncogenes/tumor suppressor genes 
(13). MiRNA expression profiles can distinguish tumors from 
corresponding normal tissues and can suggest their develop-
mental origin and differentiation state (14,15). Several studies 
have also shown that miRNAs are involved in the self-renewal 
and fate decisions of stem cells and that mechanism regulating 
the self-renewal nature of stem cells are dysfunctional in CSCs 
(16-20). Deregulation of miRNAs was recently reported in 
human OS (21-23) and it has been demonstrated that downreg-
ulation of miRNA-29 family members (miR-29a/b/c; miR-29s) 
is a frequent event evidenced in OS tissues (23). It has even 
been reported that the forced expression of miR-29s in OS 
cells inhibits cell proliferation and promotes cell apoptosis 
(24). however, little is known about the functions of miR-29s 
in human OS CSCs.
Our previous studies (11) have shown that, among the up-/
downregulated miRNAs present in 3AB-OS cells, miR-29b-1 
was highly downregulated. As targeting CSCs might permit 
a successful cure of OS, we believe that the knowledge of the 
role of miR-29b-1 in the regulation of cell growth, self-renewal 
and apoptosis in 3AB-OS CSCs might provide a new avenue 
for therapeutic interventions. Thus, in the present study, we 
examined the potential role of miR-29b-1 in 3AB-OS cells, by 
evaluating the in vitro effects of its functional overexpression.
Materials and methods
Cell culture. The human OS 3AB-OS CSCs were produced 
in our laboratory and patented (8,10). Cells were cultured as 
previously described (11).
Vector construction for miR-29b-1 expression and stable 
transfection. A 498-bp insert from the Homo sapiens chromo-
some 7 genomic sequence (GenBank EU154353.1) containing 
the mir-29b-1 gene (MI0000105) were obtained through PCR 
from 100 ng of genomic DNA derived from the human hT29 
colon cancer cell line. Amplification was performed with 
Pfu Ultra II fusion hS DNA polymerase (Stratagene, Agilent 
Technologies, Santa Clara, CA, USA) following the manufac-
turer's instructions. The following primer pairs were used, in 
which we included EcoRI and NotI restriction sites for 
mir-29b-1: mir-29b-1-for: 5'-CGATAGCGAATTCGCTGAA 
CCTTTGTCTGGGC-3'; mir-29b-1-rev: 5'-TTCATTAGCGG 
CCGCGATCACAGTTGGATCCG-3'. The corresponding 
mir-29b-1 PCR fragments was digested with EcoRI/NotI and 
cloned into a plasmid, named pCDomh, derived from the 
pCDh-CMv-MCS-EF1-copGFP (System Biosciences, 
Mountain view, CA, USA) in which we inserted a fragment 
containing puromycin resistance that was obtained from the 
pmiRzip vector (System Biosciences) through a PstI/KpnI 
digestion. pCDomh plasmid, containing mir-29b-1, was 
sequence verified (BioRep S.r.l., Milan, Italy).
3AB-OS cells were plated in 6-well dishes until they 
reached 90% confluence and then transfected with pCDH-
CMv-MCS-EF1-copGFP-T2A-PURO-miR-29b-1 or empty 
vector as a control (hereafter indicated as 3AB-OS-miR-
29b-1-GFP cells and 3AB-OS-GFP cells, respectively), 
using Lipofectamine 2000 (Invitrogen, Life Technologies 
Ltd., Monza, Italy) according to the manufacturer's instruc-
tions. Two days after transfections the cells were transferred 
into 100-mm dishes in selective medium containing 1 µg/
ml puromycin (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA); the medium was replaced every 3-4 days. A plate of 
untrasfected cells was used as a control for the selection. GFP 
(green fluorescent protein) expression of the transfected cells 
was assessed by fluorescence microscopy and flow cytometry 
to determine the transfection efficiency.
Fluorescence microscopy was performed using a Leica DM 
IRB fluorescence microscope (Leica Microsystems S.r.l., 
Milan, Italy) and images were photographed and captured by a 
computer-imaging system (Leica DC300F camera and Adobe 
Photoshop for image analysis. The GFP fluorescence was 
assayed employing a filter FITC set.
Flow cytometry analysis was performed by a Coulter 
Epics XL flow cytometer (Beckman Coulter S.r.l., Cassina De 
Pecchi, Milan, Italy) equipped with a single Argon ion laser 
(emission wavelength of 488 nm) and Expo 32 software. The 
green fluorescence was measured in the FL1 channel using a 
515-nm BP filter.
Growth curve and cell viability assays. Total cell number and 
viability were evaluated by trypan blue exclusion counting as 
previously described (25).
Cell cycle and proliferation analyses. Cell cycle phase 
distribution was studied by flow cytometry of DNA content. 
For DNA staining, trypsinized cell suspensions were centri-
fuged, washed 3 times with PBS and resuspended at 1x106 
cells/ml in PBS. Cells were mixed with cold absolute ethanol 
and stored for 1 h at 4˚C. After centrifugation, cells were 
rinsed 3 times in PBS and the pellet was suspended in 1 ml 
of propidium iodide (PI) staining solution (3.8 mM sodium 
citrate, 25 µg/ml PI, 10 µg/ml RNase A; Sigma-Aldrich S.r.l., 
Milan, Italy) and kept in the dark at 4˚C for 3 h prior to flow 
cytometry analysis. The proliferation index was calculated 
as the sum of cells in S and G2/M phases of cell cycle (26). 
Flow cytometry analyses were performed by a Coulter 
Epics XL flow cytometer (Beckman Coulter) equipped with 
a single Argon ion laser (emission wavelength of 488 nm) and 
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Expo 32 software. The red fluorescence was measured in 
the FL3 channel using a 620-nm BP filter. At least 1x104 
cells per sample were analyzed and data were stored in list 
mode files.
Flow cytometry analysis of Ki-67 expression. For intracel-
lular staining of Ki-67, at least 500,000 cells were processed 
using the Caltag Fix & Perm kit (Invitrogen) following the 
manufacturer's guidelines. The antibodies used were FITC-
conjugated anti-human/mouse Ki-67 and FITC-conjugated 
mouse IgG1k isotype control (BD Pharmingen, Buccinasco, 
Milan, Italy). Flow cytometry analysis was performed as 
reported above. The green fluorescence was measured as 
described in the above ‘vector construction for miR-29b-1 
expression and stable transfection’ paragraph. At least 1x104 
cells per sample were analyzed and data were stored in list 
mode files. Expression of cell marker was determined by 
comparison with isotype control.
Three-dimensional (3D) cell culture. The 3D Culture BME 
(Cultrex, Trevigen; Tema Ricerca S.r.l., Bologna, Italy) was 
used in the assay. Briefly, BME gel was thawed on ice over-
night at 4˚C; 300 µl of 3D BME scaffold was seeded into 
24-well plates and was then transferred to a CO2 incubator set 
at 37˚C for 30 min to promote gel formation. Cells (2.0x104) 
were seeded in DMEM (supplemented with 10% FBS) on top 
of the thick gel in each well.
Once plated on BME, all cultures were incubated at 
37˚C in a 5% CO2 humidified incubator for up to 14 days 
and media were replaced every 3 days. After 2 days, 
morphology was observed every 3 days via phase contrast 
microscopy using a Leica DM IRB inverted microscope 
(Leica Microsystems S.r.l.). Images were photographed and 
captured by a computer-imaging system (Leica DC300F 
camera and Adobe Photoshop for image analysis). Size of 
resulting structures were measured using ImageJ software.
Sarcosphere and colony formation assay. These studies were 
performed as previously described (25).
Chemosensitivity analysis. 3AB-OS-miR-29b-1-GFP cells 
and 3AB-OS-GFP cells, were cultured to 150,000 cells/
well in 6-well plates (Corning Costar, Euroclone, Pero, 
Italy) in culture medium. After 24 h cells were treated with 
250 nM doxorubicin (Calbiochem, Millipore, Darmstadt, 
Germany), 10 µM cisplatin (Sigma-Aldrich) and 5 µM 
etoposide (Calbiochem, Millipore). Cell viability was 
analyzed by the trypan blue assay previously described (25). 
Apoptotic morphology was evaluated in cells stained with 
hoechst 33342 (Sigma-Aldrich). In particular, cells were 
stained with hoechst 33342 (2.5 µg/ml medium) for 30 min 
at 37˚C and visualized by fluorescence microscopy using 
an appropriate filter for DAPI. Cells were evaluated on the 
basis of their nuclear morphology, noting the presence of 
homogeneous chromatin, condensed chromatin, and frag-
mented nuclei. Apoptosis was also studied by flow cytometry 
of DNA content as described in the above ‘Cell cycle and 
proliferation analyses’ paragraph. The proportion of cells 
giving fluorescence in the sub-G0/G1 phase of cell cycle was 
taken as a measure of apoptosis.
Scratch/wound-healing and in vitro matrigel invasion assay. 
These studies were performed as previously described (25).
RNA extraction and real-time RT-PCR. For miR-29b-1, total 
RNA extraction was performed using the Direct-zol RNA 
MiniPrep (zymo Research, Euroclone); a DNase I treatment 
step was included. cDNA synthesis was carried out on 80 ng 
of total RNA, by using the mercury LNA™ Universal RT 
microRNA PCR kit (Exiqon, Euroclone), according to the 
manufacturer's instructions. Afterwards, real-time PCR was 
performed, using 4 µl of cDNA product, miR-29b-1 LNA™ 
primers (204261; Exiqon), and SYBR Green master mix 
(Exiqon). PCR was performed under the following conditions: 
95˚C for 10 min, followed by 40 cycles of 95˚C for 10 sec and 
60˚C for 1 min.
For Oct3/4, Sox2, Nanog, CD133, N-Myc, CCND2, E2F1, 
E2F2, Bcl-2 and IAP-2, 1 µg of total RNA was reverse tran-
scribed by using the iScript™ cDNA Synthesis kit (Bio-Rad 
Laboratories S.r.l., Segrate, Milan, Italy), according to the 
manufacturer's instructions. The resulting cDNAs were used 
for quantitative analysis by real-time PCR (qPCR) using the 
IQ SYBR Green Supermix (Bio-Rad) and the QuantiTect 
primers [QuantiTect Primer assay (200); Qiagen, Milan, Italy]. 
PCR primers used were: Oct3/4 (POU5F1: QT00210840), 
Sox2 (QT00237601), Nanog (QT01025850), CD133 (PROM1: 
QT 0 0 075586),  N-Myc  (QT 0 02 014 0 4),  CC N D2 
(QT00057575), E2F1 (QT00016163), E2F2 (QT00045654), 
BCL2 (QT00025011) and IAP-2 (BIRC3: QT00021798). PCR 
cycling was performed as follows: 95˚C for 10 min; 95˚C for 
30 sec, 60˚C for 60 sec, 72˚C for 30 sec for 40 cycles and a 
final extension at 72˚C for 5 min. All real-time PCR reactions 
are performed in triplicate. To ensure that the RNA samples 
were not contaminated with genomic DNA, we included a 
no reverse transcriptase control (no RT) during each run of 
real-time RT-PCR. Furthermore, to check the accuracy of 
amplifications, we included a negative control in each run 
by eliminating the cDNA sample in the tube. Real-time PCR 
and data collection were performed on an IQ5 cycler instru-
ment (Bio-Rad) qPCR data were analyzed by IQ5 cycler 
software. The relative expressions of mRNAs and miRNAs 
were calculated using the comparative 2-∆∆Ct method and were 
normalized using GAPDh (QT01192646; Qiagen) and U6 
snRNA (203907; Exiqon), respectively.
miRNA target prediction. Genes that contain the miR-29b-
binding site(s) in the 3'-UTR were obtained using the 
TargetScan 5.1, MiRanda, PICTAR, miRbase and DIANA-
microT target prediction algorithms, as previously described 
(11).
Western blot analysis. Cells were washed in PBS and incubated 
on ice-cold lysis buffer (RIPA buffer 50 µl/106 cells) containing 
protease inhibitor cocktail (Sigma-Aldrich) for 30 min and 
sonicated three times for 10 sec. Equivalent amounts of 
proteins (40 µg) were separated by SDS-polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane 
(Bio-Rad) for detection with primary antibodies against 
Oct3/4, Sox2, Nanog, N-Myc, CCND2, E2F1, E2F2, Bcl-2, 
IAP-2 (diluted 1:300; Santa Cruz Biotechnology), CD133 
(diluted 1:250; Abgent, Flanders Court, San Diego, CA, 
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USA) and the appropriate horseradish peroxidase-conjugated 
secondary antibodies. Immunoreactive signals were detected 
using enhanced chemiluminescence (ECL) reagents (Bio-Rad). 
The correct protein loading was confirmed by stripping the 
immunoblot and reprobing with primary antibody for actin 
(diluted 1:500; Sigma-Aldrich). Bands were visualized and 
photographed with Chemi Doc XRS (Bio-Rad). Quantification 
was performed using Quantity One software.
Statistical analysis. Data, represented as mean ± SD, were 
analyzed using the two-tailed Student's t-test using Microsoft 
Excel. Differences were considered significant at P<0.05.
Results
miR-29b-1 overexpression reduces cell growth in 
3AB-OS CSCs. To examine the potential role of miR-29b-1 
in 3AB-OS CSCs, as described in Materials and methods, 
we stably transfected 3AB-OS cells with either empty 
vector (3AB-OS-GFP cells) or vector containing miR-29b-1 
(3AB-OS-miR-29b-1-GFP cells). To perform our study, 
preliminarily selected cells were used to evaluate the efficiency 
of miR-29b-1 transfection and expression. In comparison 
with phase contrast microscopy, fluorescence microscopy 
analysis (Fig. 1A) of the green fluorescent protein (GFP) 
shows a strong positivity for GFP homogeneously distributed 
in each group of transfected cells. Moreover, flow cytometry 
analysis confirmed a strong positivity for GFP (>95%). Real-
time RT-PCR analysis in both 3AB-OS-miR-29b-1-GFP and 
3AB-OS-GFP cells, in comparison with untransfected cells, 
shows increase in the expression of miR-29b-1 up to 1.55-
fold (P<0.01) in 3AB-OS-miR-29b-1-GFP cells, while no 
significant variations were measured in 3AB-OS-GFP cells 
(Fig. 1B). Thereafter, we assessed the effect of miR-29b-1 
overexpression on 3AB-OS cell proliferation. In Fig. 2A, 
phase contrast microscopy shows that cell number markedly 
decreased in 3AB-OS-miR-29b-1-GFP cells with respect to 
3AB-OS-GFP and untransfected cells. In Fig. 2B cell count 
shows that miR-29b-1 overexpression markedly reduced the 
growth rate, whereas it did not induce loss of cell viability as 
shown by trypan blue exclusion assay. In agreement, studies of 
DNA content profiles, by flow cytometry analysis of propidium 
iodide stained cells, show that 3AB-OS-miR-29b-1-GFP cells 
were mostly in the G0/G1 phase, while untransfected and 
3AB-OS-GFP cells were predominantly in S-G2/M (Fig. 2C). 
Moreover, analysis of the proliferation marker Ki-67 shows 
that 3AB-OS-miR-29b-1-GFP cells resulted to be less Ki-67-
positive than untransfected and 3AB-OS-GFP cells (Fig. 2D). 
During our studies statistically significant difference between 
untransfected 3AB-OS cells and 3AB-OS-GFP cells were 
never observed (P>0.05). Therefore, we decided to employ 
3AB-OS-GFP cells as control.
We analyzed the effects of miR-29b-1 overexpression in a 
three-dimensional (3D) culture model on Matrigel. As shown 
in Fig. 2E, 3AB-OS-miR-29b-1-GFP cells grew slower than 
3AB-OS-GFP cells. Indeed, after 2 and 5 days in culture 
3AB-OS-miR-29b-1-GFP cells formed spherical masses of 
cells smaller than that of 3AB-OS-GFP cells, suggesting a 
decrease of cell proliferation. After eight days, cell cluster 
density continued to increase in size, often appearing darker 
and denser; however, 3AB-OS-miR-29b-1-GFP clusters were 
much smaller than 3AB-OS-GFP clusters. Moreover, at this 
time, 3AB-OS-GFP clusters even generated multi-cellular 
sphere structures not evidenced in 3AB-OS-miR-29b-1-GFP 
clusters. From day 11 to 14, the structures of both cell lines 
gradually lost their spatial separation, tending to fuse into 
a single structure. Moreover, during this time they did not 
appreciably change in size, suggesting a cessation of prolifera-
Figure 1. Evaluation of efficiency of miR-29b-1 transfection and expression in 3AB-OS cells. (A) Phase contrast (left panels) and fluorescence (middle panels) 
images of 3AB-OS-GFP cells (top panels) or 3AB-OS-miR-29b-1-GFP cells (bottom panels). The scale bar represents 100 µm. Cytometric analysis for the 
green fluorescent protein (GFP) expression (right panels) in 3AB-OS-GFP cells (top panel) and 3AB-OS-miR-29b-1-GFP cells (bottom panel). The open 
histogram indicates negative control (untransfected cells), filled histogram indicates the expression of GFP. Images are representative of four independent 
experiments. (B) Real-time RT-PCR analysis of miR-29b-1 in 3AB-OS untransfected cells, 3AB-OS-GFP cells and 3AB-OS-miR-29b-1-GFP cells. Data 
represent the mean with standard deviation (n=4); *P<0.01 as compared to untransfected cells.
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tion. We even performed the progressive quantification of the 
sizes of the structures formed by the two cell lines in 3D. As 
shown in Fig. 2F, from day 2 to 8 the size of the structures 
resulting from 3D culture in Matrigel, were significantly 
different among the two cells lines. Indeed, at days 2, 5 and 8 
the mean diameter of 3AB-OS-miR-29b-1-GFP structures 
(25.3±9, 41.3±12 and 90.9±28.6 µm, respectively) were 
smaller than those of 3AB-OS-GFP cells measured at the 
same times (30.5±7.5, 78.5±20.5 and 125.5±28 µm, respec-
tively). At days 11 and 14, when the cell structures were 
stabilized and proliferation ceased, there was not significant 
difference among the two cells lines. At this stage, cell 
density might have reached the highest level, thus, the oxygen 
and nutrient supply by passive diffusion might have no longer 
been able to meet the need of the cell growth, nor to support 
the cell clusters to grow any more. Overall, the results suggest 
that in 3D culture 3AB-OS-miR-29b-1-GFP cells grow more 
slowly than 3AB-OS-GFP cells.
miR-29b-1 overexpression decreases self-renewal in 
3AB-OS CSCs. To test whether miR-29b-1 is important for 
3AB-OS cells self-renewal, we tested, under non-adherent 
conditions (27), sarcosphere-forming ability of 3AB-OS-miR-
29b-1-GFP cells compared to 3AB-OS-GFP cells. Fig. 3A 
shows that both cell lines were capable of forming sarcospheres. 
In particular, after days 5 in culture, 3AB-OS-GFP cells 
Figure 2. Effect of miR-29b-1 overexpression on growth and proliferation of 3AB-OS cells. (A) Phase contrast microscopy images at days 1-4 of untrans-
fected cells (top panels), 3AB-OS-GFP cells (middle panels) and 3AB-OS-miR-29b-1-GFP cells (bottom panels) in culture. The scale bar represents 100 µm. 
Images are representative of four independent experiments. (B) Growth curves (cell number) and cell viability of untransfected cells, 3AB-OS-GFP cells 
and 3AB-OS-miR-29b-1-GFP cells. Data represent the mean with standard deviation (n=4); *P<0.05 as compared to untransfected cells. (C) Cell cycle 
distributions determined using flow cytometry. Results are indicated as relative percentage of total cell cycle (*P<0.05, as untransfected cells). (D) Graph 
summarizing Ki-67 reactivity. Data represent the mean with standard deviation (n=4); *P<0.05 as compared to untransfected cells. (E) Phase contrast 
microscopy images of 3AB-OS-GFP cells (top panels) and 3AB-OS-miR-29b-1-GFP cells (bottom panels) in a three-dimensional (3D) culture model 
on Matrigel. The black arrows indicate multi-cellular shere structures. The scale bar represents 200 µm. Images are representative of four independent 
experiments. (F) Graphs summarizing size of spherical masses from 3AB-OS-GFP and 3AB-OS-miR-29b-1-GFP cells cultured in 3D (on days 2, 5, 8, 11 
and 14). Data represent the mean with standard deviation (n=4); *P<0.05, **P<0.01 as compared to 3AB-OS-GFP cells.
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formed sarcospheres having a mean diameter of 70.5±14.2 µm, 
at a frequency of ~1/14 (36.6±4.5 spheres/500 cells), while 
3AB-OS-miR-29b-1-GFP cells formed smaller sarcospheres 
(mean diameter of 61.2±11.3 µm) at a frequency of ~1/19 
(26.3±6.5 spheres/500 cells). After 10 days, 3AB-OS-GFP 
sarcospheres increased in size and number, reaching a mean 
diameter of 92.9±28 µm, containing ~1,072 cells/sphere. Even 
3AB-OS-miR-29b-1-GFP sarcospheres increased in size and 
number, but they were fewer in number and much smaller 
(mean diameter of 78.6±23 µm, containing ~875 cells/sphere). 
On analyzing sarcosphere-forming ability through subsequent 
passages (secondary and tertiary spheres), we found (Fig. 3B) 
that the number of sarcospheres generated from both cell 
lines in each passage remained consistent; however, 3AB-OS-
miR-29b-1-GFP cells formed ~1.4-fold less sarcospheres 
than 3AB-OS-GFP cells, demonstrating that miR-29b-1 
decreases the self-renewal capacity of sarcosphere-forming 
cells. In addition, in a colony-forming assay that correlates 
with self-renewal (28), 3AB-OS-miR-29b-1-GFP cells formed 
less numerous and smaller colonies than 3AB-OS-GFP cells 
(Fig. 3C). These data suggest that miR-29b-1 controls the 
growth and self-renewal capacity of 3AB-OS CSCs.
miR-29b-1 overexpression enhances the chemosensitivity of 
3AB-OS CSCs. We next investigated whether miR-29b-1 could 
also enhance chemosensitivity of 3AB-OS cells. Fig. 4A and B 
Figure 3. Effect of miR-29b-1 overexpression on sarcosphere- and colony-forming ability of 3AB-OS cells. (A) Phase contrast images of primary 
sarcospheres formed from 3AB-OS-GFP and 3AB-OS-miR-29b-1-GFP cells after 5 and 10 days of culturing. The scale bar represents 50 µm. Graphs 
summarizing size and number of sarcospheres from 500 cells (days 5 and 10) and number of cells/sphere on day 10. Data represent the mean with standard 
deviation (n=4); *P<0.05 as compared to 3AB-OS-GFP cells. (B) Graph summarizing numbers of primary, secondary (generated from dissociated primary 
spheres) and tertiary (generated from dissociated secondary spheres) sarcospheres on day 10 from 500 cells. Data represent the mean with standard 
deviation (n=4); *P<0.05 as compared to 3AB-OS-GFP cells. (C) Clonogenic growth of 3AB-OS-GFP and 3AB-OS-miR-29b-1-GFP cells after 10 days 
of culture. Phase contrast images (top; the scale bar represents 100 µm) and an image (bottom) of 6-well plate after staining with methylene blue. Graphs 
summarizing plate efficiency (colonies/100 cells) and relative colony size (mean area relative to 3AB-OS-GFP cells). Data represent the mean with standard 
deviation (n=4); *P<0.05 as compared to 3AB-OS-GFP cells.
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(left panels) show that exposure of the cells to doxorubicin or 
cisplatin, two of the major drugs used for the chemotherapy 
of osteosarcoma (3,4), resulted in significant time-dependent 
reduced viability of 3AB-OS-miR-29b-1-GFP cells with 
respect to 3AB-OS-GFP cells. Furthermore, both morpho-
logical examination (data not shown) and flow cytometry 
assay of DNA content (percentage of cells in the sub-G0/
G1 phase of cell cycle, taken as a measure of apoptosis) 
demonstrated that drug treatment induced in 3AB-OS-miR-
29b-1-GFP cells a percentage of apoptosis much higher 
than in 3AB-OS-GFP cells (Fig. 4A and B, right panels). 
Fig. 4C shows that 3AB-OS-miR-29b-1-GFP cells were also 
much more sensitive to etoposide-induced apoptosis than 
3AB-OS-GFP cells. These results suggest that miR-29b-1 
may increase the sensitivity of 3AB-OS cells to different 
chemotherapeutic agents.
MiR-29b-1 overexpression does not influence migratory and 
invasive capacities of 3AB-OS CSCs. To evaluate whether 
miR-29b-1 overexpression influences the motility and inva-
sivity of 3AB-OS cells, we performed scratch/wound healing 
and Matrigel Transwell invasion assays, respectively. In 
Fig. 5A and B the data from the wound-healing repair assay at 
8, 24 and 32 h after scratching, show no significant differences 
(P>0.05) in migratory capacity between 3AB-OS-miR-29b-
1-GFP cells and 3AB-OS-GFP cells. Similarly, no differences 
were observed in the cell invasive capacity between the two 
cell lines, as shown by Matrigel Transwell invasion assays 
(Fig. 5C and D).
miR-29b-1 overexpression reduces the expression of stem-
cell, cell cycle and anti-apoptotic markers in 3AB-OS CSCs. 
To predict the possible molecular target of miR-29b, we 
employed a number of avaible databases (TargetScan 5.1, 
MiRanda, PICTAR, miRbase and DIANA-microT). The 
analysis predicted a great number of targets know to be strong 
regulators of stemness, cell cycle and apoptosis (not shown). 
Among these we analyzed CD133, N-Myc, CCND2, E2F1 
and E2F2, Bcl-2 and IAP-2, since they are overexpressed 
in 3AB-OS cells (8,11) and many of them were found to be 
frequently overexpressed in tissues of osteosarcoma patients 
(29-35). We also analyzed Oct3/4, Sox2 and Nanog, as they 
are the most important stemness markers previously found to 
be overexpressed in 3AB-OS CSCs (8,10). In Fig. 6A western 
blot analysis shows that in 3AB-OS-miR-29b-1-GFP cells 
protein levels of important stem cell markers (Oct3/4, Sox2, 
Nanog, CD133, N-Myc), cell cycle-related markers (CCND2, 
E2F1, E2F2) and anti-apoptotic markers (Bcl-2 and IAP-2) 
were markedly lower than in 3AB-OS-GFP cells. Moreover, 
real-time RT-PCR analysis (Fig. 6B) shows that, similarly, 
the level of mRNAs related to the above reported proteins 
were markedly lower in 3AB-OS-miR-29b-1-GFP cells than 
in 3AB-OS-GFP cells. These data suggest that miR-29b-1 
may negatively regulate the expression of these markers and 
that its overexpression probably affects cell proliferation, 
self-renewal and chemosensitivity of 3AB-OS CSCs by 
directly or indirectly targeting their mRNAs.
Discussion
MicroRNAs (miRNAs) are a class of non-coding regula-
tory RNAs of ~22 nucleotides (12) that are able to bind to 
specific sites typically present in the 3'-UTR of their target 
genes. They mediate either mRNA decay with perfect 
base pairing or translational blockade with imperfect 
base pairing (36). As miRNAs may act as oncogenes or 
tumor suppressor genes (13), they constitute a large gene 
regulatory network that can modulate proliferation, cancer, 
and stemness. This suggests that they might be novel 
biomarkers or therapeutic targets in cancer treatment. In 
recent years, it has been found that miRNAs are involved 
in tumorigenesis and carcer progression and that family of 
miR29s is aberrantly expressed in multiple cancers (37). 
A large body of studies has provided results on functions 
of miR29s in cancer, even suggesting their targeting for 
cancer therapy. Nevertheless, their functional mechanisms 
relevant to cancer are poorly understood.
Figure 4. Effect of miR-29b-1 overexpression on chemosensitivity of 3AB-OS 
cells. Both 3AB-OS-GFP cells and 3AB-OS-miR-29b-1-GFP cells were 
treated with (A) doxorubicin (250 nM); (B) cisplatin (10 µM); and (C) etopo-
side (5 µM) for indicated times. Cell viability (left panels) was determined by 
trypan blue exclusion assay; apoptosis (right panels) was evaluated by flow 
cytometric analysis of propidium iodide DNA staining (percentages of cells 
in sub-G0/G1 phase). Data represent the mean with standard deviation (n=4); 
*P<0.05, **P<0.01 and #P<0.005 as compared to 3AB-OS-GFP cells.
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Figure 5. Effects of miR-29b-1 overexpression on migratory and invasion ability of 3AB-OS cells. (A) Representative images from the scratch wound-
healing assay in 3AB-OS-GFP cells (top panels) and 3AB-OS-miR-29b-1-GFP cells (bottom panels). Cells were scratched and wound margins were 
imaged 0, 8, 24 and 32 h later. The scale bar represents 100 µm. (B) Quantification of the scratch wound-healing assay. The extent of wound closure was 
quantified by measuring the wound area compared to the initial wound area. Data represent the mean with standard deviation (n=4; P>0.05 as compared 
to 3AB-OS-GFP cells). (C) Graphs summarizing relative invasion (mean of the percentage of the number of cells relative to 3AB-OS-GFP cells). Data 
represent the mean with standard deviation (n=4; P>0.05 as compared to 3AB-OS-GFP cells). (D) Representative images from the transwell invasion 
assays in 3AB-OS-GFP and 3AB-OS-miR-29b-1-GFP cells. After 48 h of incubation, cells migrated to the underside of the insert were stained with 
hoechst 33342. The scale bar represents 50 µm.
Figure 6. Effects of miR-29b-1 overexpression on stem-cell, cell cycle and anti-apoptotic marker expression in 3AB-OS cells. (A) Western blot analysis of 
stemness, cell cycle and anti-apoptotic proteins. Expression level relative to 3AB-OS-GFP cells is shown below the blots. The results are representative of 
four independent experiments. (B) Real-time RT-PCR analysis of mRNAs related to the above reported proteins. Data represent the mean with standard 
deviation (n=4); *P<0.05 and **P<0.01 as compared to 3AB-OS-GFP cells.
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It has been demonstrated that downregulation of the family 
of miR29s is a frequent event in OS tissues (23) and that its 
forced expression in OS cells inhibits cell proliferation and 
promotes cell apoptosis (24). however, their biological func-
tions and possible mechanisms of action in OS CSCs have not 
been elucidated.
We have previously shown (11) that, in comparison with 
parental MG63 cells, 3AB-OS cells revealed miR-29b mark-
edly downregulated. here, we investigated the potential 
contribution of miR-29b-1 to 3AB-OS stemness. To perform 
these studies we upregulated miR-29b-1 in 3AB-OS cells; 
then, we examined the effects of this overexpression on cell 
proliferation, sarcosphere-forming ability, clonogenic growth, 
chemosensitivity, migration and invasive ability of 3AB-OS-
miR-29b-1-GFP cells.
Our results demonstrated that in 3AB-OS-miR-29b-1-GFP 
cells proliferation was markedly reduced in both two- and 
three-dimensional culture systems. Furthermore, miR-29b-1 
overexpression significantly downregulated protein and 
mRNA levels of its putative targets CCND2, E2F1 and E2F2. 
These putative targets are known to be involved in cell cycle 
regulation and DNA synthesis (38). Interestingly, it has been 
reported that miR-29s target CCND2 in various cancer types 
(39,40) and E2F1 in OS (24). E2F1 and E2F2 are members of 
the E2F family of transcription factors, and have been well-
characterized as regulators of the G1-S phase transition (41). 
Previous reports indicate that E2F2 has strong oncogenic 
capacity and that cell lines transfected with E2F2 proliferate 
at twice the rate of control cells (42). For proper progression 
through cell cycle, phosphorylation activity of cyclin depen-
dent kinase (Cdk) is essential. It is well known that CCNDs 
bind Cdk4 and Cdk6 (43) with consequent activation of Rb 
phosphorylation which inhibits Rb activity and activates 
E2Fs, allowing S-phase entry. Accordingly, overexpression 
of CCND2, E2F1 and E2F2 were reported in various cancer 
types, including OS (32,33).
In our previous study (8) we have shown that 3AB-OS 
cells have highly deregulated Rb function. Indeed, the analysis 
of its functional status evidenced that, in respect to parental 
MG63 cells, 3AB-OS cells express much higher levels of 
the hyperphosphorylated/inactive Rb form. Moreover, this is 
accompanied by CCND2 overexpression (11) and by very high 
levels of nuclear β-catenin (8) which also strongly correlated 
to cancer invasivity (44,45). Thus, the potent downregulation 
of miR-29b-1 in 3AB-OS cells might be at the root of their 
altered G1-S transition.
In this study, we also found that miR-29b-1 overexpression, 
in 3AB-OS CSCs, consistently reduced their sarcosphere-
forming ability and colony formation. Moreover, in comparison 
with 3AB-OS-GFP cells, 3AB-OS-miR-29b-1-GFP cells also 
showed potently decreased stemness marker levels (Oct3/4, 
Sox2, Nanog, CD133 and N-Myc). Intriguingly, among them, 
CD133 and N-Myc are putative targets of miR-29b and CD133 
is a recognized stem cell marker used for the identification 
and isolation of putative cancer stem cell populations from 
various malignant tumors, including OS (29,30). In particular, 
it is known that N-Myc gene has an essential role in normal 
hematopoietic stem cell function, and that in medulloblastoma 
genesis it is also responsible for the transformation of stem 
cells to CSCs (46,47). Oct3/4, Nanog, and Sox-2 are essential 
transcription factors critically involved in both self-renewal 
and maintenance of pluri/multipotency of undifferentiated 
embryonic/adult stem cells (48,49). Of great interest is that all 
of these genes are overexpressed in 3AB-OS cells and many 
of them were found to be frequently overexpressed in tissues 
of OS patients (31-33) and in stem cells isolated from OS cell 
populations (29,30). This suggests that expression of these 
genes may be a main feature of CSCs. Overall, these findings 
suggested that the deep downregulation of miR-29b-1 found 
in 3AB-OS CSCs might play a key role in regulating their 
stemness.
It is known that the reluctance of the cells to enter 
apoptosis could be an important cause of therapeutic 
resistance. We have previously shown that, in comparison 
with parental MG63 cells, 3AB-OS cells highly express 
a greater number of genes required for inhibiting apop-
tosis (FlipL, Bcl-2, XIAP, IAP1, IAP-2, and survivin) (8). 
herein we show that miR-29b-1 overexpression sensitized 
3AB-OS cells to chemotherapeutic drug-induced apoptosis 
and concomitantly decreased the expression of the anti-
apoptotic genes Bcl-2 and IAP-2. The overexpression of 
Bcl-2 and IAP-2 has been identified in a variety of human 
cancers (50,51) and it has been reported that miR-29s target 
Bcl-2 in both hepatocellular carcinoma (hCC) and OS cell 
line (52,24).
Moreover, it has been shown (53) that miR-29b acts as an 
antimetastatic miRNA for prostate cancer cells at multiple 
steps in a metastatic cascade. however, in contrast, it has 
been shown that miR-29a can lead to epithelial-mesenchymal 
transition and metastasis in cooperation with oncogenic 
Ras signaling (54). This suggested that the role of miR-29s 
in cancer may depend on the context. herein, our results 
showing that miR-29b-1 overexpression did not influence 
migratory and invasive capacities of 3AB-OS cells, agree 
with the role of the context in determining the effects of the 
family of miR-29s.
In conclusion, our study demonstrated that miR-29b-1 
overexpression causes 3AB-OS CSCs proliferation, self-
renewal and chemosensitivity. This is accompanied by 
downregulation of key stem cell markers (Oct3/4, Sox2, 
Nanog, CD133, N-Myc), cell cycle-related markers (CCND2, 
E2F1, E2F2) and anti-apoptotic markers (Bcl-2 and IAP-2). 
Overall, the results show that miR-29b-1 suppresses stem-
ness properties of 3AB-OS CSCs and suggest that developing 
miR-29b-1 as a novel therapeutic agent might offer benefits 
for OS treatment.
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